Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lin Shen, PhD
Peking University Cancer Hospital & Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Anhui Provincial Hospital
Hefei, Anhui, China
Completed - Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Recruiting - Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Active, not recruiting - Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Completed - the Affiliated Hospital of Military Medical Sciences
Beijing, Beijing Municipality, China
Completed - Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Recruiting - Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Active, not recruiting - Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China
Completed - Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Completed - the Sixth Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong, China
Completed - Huizhou First Hospital
Huizhou, Guangdong, China
Recruiting - Meizhou People Hospital
Meizhou, Guangdong, China
Recruiting - the Peoples Hospital of Hechi
Hechi, Guangxi, China
Active, not recruiting - Affiliated Hospital of Hebei University
Baoding, Hebei, China
Completed - Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Recruiting - Henan Cancer Hospital
Zhengzhou, Henan, China
Completed - Hubei Cancer Hospital
Wuhan, Hubei, China
Completed - Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Completed - Hunan Cancer Hospital
Changsha, Hunan, China
Completed - Jiangsu Province Hospital
Nanjing, Jiangsu, China
Completed - Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Completed - Jilin Cancer Hospital
Changchun, Jilin, China
Completed - the General Hospital of Shenyang Military
Shenyang, Liaoning, China
Completed - Yidu Central Hospital of Weifang
Weifang, Shandong, China
Completed - Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Completed - Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Completed - the First Peoples Hospital of Yibin
Yibin, Sichuan, China
Active, not recruiting - the First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Completed - Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Completed - Zhejiang University College of Medicine Second Affiliated Hospital
Hangzhou, Zhejiang, China
Completed
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Sept 2018
- Primary completion
- 30 Nov 2026
- Completion
- 30 Sept 2027
- Last update posted
- 10 Jul 2026
- Registered enrollment
- 200
- Registry id
- NCT03736889
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.